The present disclosure relates to recombinant microorganisms having an improved ethylene producing ability, methods of producing the same, and methods of harvesting ethylene from such recombinant organisms. A benefit of the recombinant microorganisms and the methods disclosed herein can include increased production of ethylene from microbial cultures. An additional benefit can be the use of carbon dioxide to produce bio-ethylene useful as a feedstock for the production of plastics, textiles, and chemical materials, and for use in other applications. Another benefit of the methods and systems disclosed herein can include reduction of excess carbon dioxide from the environment.
The increased demand for power worldwide has led to an excess of carbon dioxide from burning fossil fuels such as oil and gas, contributing substantially to what many are calling a global warming crisis. Industry is so desperate to prevent carbon dioxide from entering the atmosphere that they have resorted to sequestering carbon dioxide from exhaust streams and the atmosphere. They then store the carbon dioxide in subterranean environments. However, all current known methods just remove carbon dioxide from the atmosphere by storing it under ground. They do not actually convert the carbon dioxide back into any other useful material.
The limited supply of petroleum and its harmful effects on the environment have prompted developments in renewable sources of fuels and chemicals. Ethylene is the most widely produced organic compound in the world, useful in a broad spectrum of industries including plastics, solvents, and textiles. Ethylene is currently produced by steam cracking fossil fuels or dehydrogenating ethane. With millions of metric tons of ethylene being produced each year, however, more than enough carbon dioxide is produced by such processes to greatly contribute to the global carbon footprint. Producing ethylene through renewable methods would accordingly help to meet the huge demand from the energy and chemical industries, while also helping to protect the environment.
Since ethylene is a potentially renewable feedstock, there has been a great deal of interest in developing technologies to produce ethylene from renewable sources, such as carbon dioxide and biomass. Bio-ethylene is currently produced using ethanol derived from corn or sugar cane. A variety of microbes, including bacteria and fungi, naturally produce ethylene in small amounts. Heterologous expression of an ethylene producing enzyme has been demonstrated in several microbial species, where the hosts have been able to utilize a variety of carbon sources, including lignocellulose and carbon dioxide.
Based on modern history, it is fair to say that excess carbon dioxide in the atmosphere will not be reduced until it becomes profitable to reduce it. There remains a need for improvements in microbial bio-ethylene systems and processes, in order to produce ethylene at a commercial scale. There remains a need to produce hydrocarbons through more efficient renewable technologies. There remains a need to remove excess carbon dioxide from the atmosphere. There remains a need for improved methods to produce ethylene from a renewable feedstock for industrial and commercial applications.
Embodiments herein are directed to a recombinant microorganism having an improved ethylene producing ability, wherein the recombinant microorganism expresses at least one ethylene forming enzyme (EFE) protein having an amino acid sequence at least 95% identical to SEQ ID NO: 1 (see attached Appendix) by expressing a non-native EFE expressing nucleotide sequence, wherein an amount of EFE protein produced by the recombinant microorganism is greater than that produced relative to a control microorganism lacking the non-native EFE expressing nucleotide sequence. In an embodiment, the recombinant microorganism also expresses at least one alpha-ketoglutarate permease (AKGP) protein having an amino acid sequence at least 95% identical to SEQ ID NO: 2 (see attached Appendix) by expressing a non-native AKGP expressing nucleotide sequence, wherein an amount of AKGP protein produced by the recombinant microorganism is greater than that produced relative to a control microorganism lacking the non-native AKGP expressing nucleotide sequence. In an embodiment, the amount of EFE protein produced by the recombinant microorganism is from about 5% to about 200% or more greater than that produced relative to the control microorganism lacking the non-native EFE expressing nucleotide sequence.
In various embodiments, the recombinant microorganism includes a Cyanobacteria, a Synechococcus, Synechococcus elongatus, Synechococcus leopoliensis, Synechocystis, Anabaena, a Pseudomonas, Pseudomonas syringae, Pseudomonas savastanoi, Chlamydomonas, Chlamydomonas reinhardtii, Escherichia, Escherichia coli, Geobacteria, algae, microalgae, electrosynthesis bacteria, a photosynthetic microorganism, yeast, filamentous fungi, or a plant cell.
In an embodiment, the non-native EFE expressing nucleotide sequence is inserted into a bacterial vector plasmid, a high copy number bacterial vector plasmid, a bacterial vector plasmid having an inducible promoter, a nucleotide guide of a homologous recombination system, a CRISPR CAS system, a phage display system, or a combination thereof. In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 95% identical to SEQ ID NO. 3 (see attached Appendix), and the non-native EFE expressing nucleotide sequence is inserted into a vector plasmid of a Chlamydomonas sp. bacterium.
In an embodiment, a non-native EFE expressing nucleotide sequence and a non-native AKGP expressing nucleotide sequence are inserted into a bacterial vector plasmid, a high copy number bacterial vector plasmid, a bacterial vector plasmid having an inducible promoter, a nucleotide guide of a homologous recombination system, a CRISPR CAS system, a phage display system, or a combination thereof. In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 95% identical to SEQ ID NO. 4 (see attached Appendix), and the non-native EFE expressing nucleotide sequence and the AKGP expressing nucleotide sequence are inserted into a vector plasmid of an Escherichia sp. bacterium.
In an embodiment, the recombinant microorganism further includes a non-native AKGP expressing nucleotide sequence, wherein the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence express a combined amino acid sequence at least 95% identical to SEQ ID NO. 5 (see attached Appendix), and the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence are inserted into a bacterial plasmid of a Synechococcus sp. bacterium. In another embodiment, the recombinant microorganism further includes a non-native AKGP expressing nucleotide sequence, wherein the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence express a combined amino acid sequence at least 95% identical to SEQ ID NO. 6 (see attached Appendix), and the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence are inserted into a bacterial plasmid of a Synechococcus sp. bacterium.
In certain embodiments, the recombinant microorganism expresses at least one phosphoenolpyruvate synthase (PEP) protein having an amino acid sequence at least 95% identical to SEQ ID NO. 15 by expressing a non-native PEP expressing nucleotide sequence, wherein an amount of PEP protein produced by the recombinant microorganism is greater than that produced relative to a control microorganism lacking the non-native PEP expressing nucleotide sequence, and wherein an amount of AKG produced by the recombinant microorganism is greater than that produced relative to the control microorganism. In certain such embodiments, the recombinant microorganism includes a microorganism selected from the group consisting of a Cyanobacteria, a Synechococcus, Synechococcus elongatus, Synechococcus leopoliensis, Synechocystis, Anabaena, a Pseudomonas, Pseudomonas syringae, Pseudomonas savastanoi, Chlamydomonas, Chlamydomonas reinhardtii, Escherichia, Escherichia coli, Geobacteria, algae, microalgae, electrosynthesis bacteria, a photosynthetic microorganism, yeast, filamentous fungi, and a plant cell.
In certain embodiments, the recombinant microorganism expresses at least one phosphoenolpyruvate synthase (PEP) protein having an amino acid sequence at least 95% identical to SEQ ID NO. 15 by expressing a non-native PEP expressing nucleotide sequence, wherein an amount of PEP protein produced by the recombinant microorganism is greater than that produced relative to a control microorganism lacking the non-native PEP expressing nucleotide sequence, and wherein an amount of AKG produced by the recombinant microorganism is greater than that produced relative to the control microorganism.
In certain embodiments, the recombinant microorganism expresses at least one citrate synthase protein having an amino acid sequence at least 95% identical to SEQ ID NO. 17 by expressing a non-native citrate synthase expressing nucleotide sequence, wherein an amount of citrate synthase protein produced by the recombinant microorganism is greater than that produced relative to a control microorganism lacking the non-native citrate synthase expressing nucleotide sequence.
In certain embodiments, the recombinant microorganism expresses at least one isocitrate dehydrogenase (IDH) protein having an amino acid sequence at least 95% identical to SEQ ID NO. 20 by expressing a non-native IDH expressing nucleotide sequence, wherein an amount of IDH protein produced by the recombinant microorganism is greater than that produced relative to a control microorganism lacking the non-native IDH expressing nucleotide sequence, and wherein an amount of AKG produced by the recombinant microorganism is greater than that produced relative to the control microorganism.
In certain embodiments, the recombinant microorganism contains a deletion in a glucose-1-phosphate adenylyltransferase expressing nucleotide sequence, wherein an amount of glucose-1-phosphate adenylyltransferase protein produced by the recombinant microorganism is less than that produced relative to a control microorganism lacking the deletion.
In certain embodiments, the recombinant microorganism expresses at least one sucrose permease protein having an amino acid sequence at least 95% identical to SEQ ID NO. 24 by expressing a non-native sucrose permease expressing nucleotide sequence,
wherein an amount of sucrose permease protein produced by the recombinant microorganism is greater than that produced relative to a control microorganism lacking the non-native sucrose permease expressing nucleotide sequence.
In certain embodiments, the recombinant microorganism expresses at least one sucrose permease protein having an amino acid sequence at least 95% identical to SEQ ID NO. 24 by expressing a non-native sucrose permease expressing nucleotide sequence,
wherein an amount of sucrose permease protein produced by the recombinant microorganism is greater than that produced relative to a control microorganism lacking the non-native sucrose permease expressing nucleotide sequence.
In certain embodiments, the recombinant microorganism expresses at least one sucrose permease protein having an amino acid sequence at least 95% identical to SEQ ID NO. 24 by expressing a non-native sucrose permease expressing nucleotide sequence,
wherein an amount of sucrose permease protein produced by the recombinant microorganism is greater than that produced relative to a control microorganism lacking the non-native sucrose permease expressing nucleotide sequence.
In certain embodiments, the recombinant microorganism expresses at least one protein selected from the group consisting of a sucrose phosphate synthase protein having an amino acid sequence at least 95% identical to SEQ ID NO. 26, a sucrose-6-phosphatase protein having an amino acid sequence at least 95% identical to SEQ ID NO. 28, a glycogen phosphorylase protein having an amino acid sequence at least 95% identical to SEQ ID NO. 30, and a UTP-glucose-1-phosphate uridylyltransferase protein having an amino acid sequence at least 95% identical to SEQ ID NO. 32, by expressing a non-native nucleotide sequence encoding the at least one protein, wherein an amount of the at least one protein produced by the recombinant microorganism is greater than that produced relative to a control microorganism lacking the non-native nucleotide sequence encoding the at least one protein, wherein an amount of sucrose produced by the recombinant microorganism is greater than that produced relative to the control microorganism.
In certain embodiments, the recombinant microorganism contains at least one deletion in at least one nucleotide sequence, wherein the at least one nucleotide sequence encodes at least one protein selected from an invertase protein having an amino acid sequence at least 95% identical to SEQ ID NO. 34, a glucosylglycerol-phosphate synthase protein having an amino acid sequence at least 95% identical to SEQ ID NO. 36, and a glycogen synthase protein having an amino acid sequence at least 95% identical to SEQ ID NO. 38, wherein an amount of the at least one protein produced by the recombinant microorganism is less than that produced relative to a control microorganism lacking the at least one deletion.
Embodiments herein are directed to methods of producing a recombinant microorganism having an improved ethylene producing ability. In an embodiment, the method includes producing the recombinant microorganism by inserting a non-native EFE expressing nucleotide sequence or a combined non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence into a bacterial plasmid of a microorganism, wherein the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 95% identical to SEQ ID NO. 3 or SEQ ID NO. 4. In another embodiment, the combined non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence expresses an amino acid sequence at least 95% identical to SEQ ID NO. 5 or SEQ ID NO. 6. In another embodiment, the combined non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence has a nucleotide sequence at least 95% identical to SEQ ID NO. 7 (See Appendix).
In various embodied methods, the microorganism includes a Cyanobacteria, a Synechococcus, Synechococcus elongatus, Synechococcus leopoliensis, Synechocystis, Anabaena, a Pseudomonas, Pseudomonas syringae, Pseudomonas savastanoi, Chlamydomonas, Chlamydomonas reinhardtii, Escherichia, Escherichia coli, Geobacteria, algae, microalgae, electrosynthesis bacteria, a photosynthetic microorganism, yeast, filamentous fungi, or a plant cell.
In an embodiment of methods herein, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 95% identical to SEQ ID NO. 3 and the microorganism is a Chlamydomonas sp. bacterium. In another embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 95% identical to SEQ ID NO. 4 and the microorganism is an Escherichia sp. bacterium. In another embodiment, the combined non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence expresses an amino acid sequence at least 95% identical to SEQ ID NO. 5 or SEQ ID NO. 6, and the microorganism is a Synechococcus sp. bacterium. In another embodiment, the combined non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence has a nucleotide sequence at least 95% identical to SEQ ID NO. 7 and the microorganism is Synechococcus sp. bacterium.
Methods of producing ethylene are embodied herein. An embodiment of such a method includes providing a recombinant microorganism having an improved ethylene producing ability, wherein the recombinant microorganism expresses at least one ethylene forming enzyme (EFE) protein having an amino acid sequence at least 95% identical to SEQ ID NO: 1 by expressing a non-native EFE expressing nucleotide sequence, wherein an amount of EFE protein produced by the recombinant microorganism is greater than that produced relative to a control microorganism lacking the non-native EFE expressing nucleotide sequence; culturing the recombinant microorganism in a bioreactor culture vessel under conditions sufficient to produce ethylene in the bioreactor culture vessel; and harvesting ethylene from the bioreactor culture vessel.
In an embodiment of methods of producing ethylene herein, the recombinant microorganism contains a non-native EFE expressing nucleotide sequence or a combined non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence inserted into a bacterial plasmid of the microorganism, wherein the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 95% identical to SEQ ID NO. 3 or SEQ ID NO. 4. In another embodiment, the combined non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence has a nucleotide sequence at least 95% identical to SEQ ID NO. 7. In another embodiment, the combined non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence expresses an amino acid sequence at least 95% identical to SEQ ID NO. 5 or SEQ ID NO. 6.
In various embodiments of producing ethylene herein, the recombinant microorganism includes a Cyanobacteria, a Synechococcus, Synechococcus elongatus, Synechococcus leopoliensis, Synechocystis, Anabaena, a Pseudomonas, Pseudomonas syringae, Pseudomonas savastanoi, Chlamydomonas, Chlamydomonas reinhardtii, Escherichia, Escherichia coli, Geobacteria, algae, microalgae, electrosynthesis bacteria, a photosynthetic microorganism, yeast, filamentous fungi, or a plant cell.
An embodiment of a method of producing ethylene further includes increasing an amount of ethylene production by adding at least one activator to a culture containing the recombinant microorganism located within the bioreactor culture vessel. In an embodiment, such a method includes adding CO2 to a culture atmosphere contained within the bioreactor culture vessel at rate of between about 100 ml/minute and about 500 ml/minute. In an embodiment, such a method further includes decreasing an amount of ethylene production by removing at least one molecular switch from the cell culture containing the recombinant microorganism located within the bioreactor culture vessel. In an embodiment, such a method further includes controlling the amount of ethylene produced from the microbial culture by increasing or decreasing the concentration of at least one nutrient or the amount of at least one stimulus when culturing the recombinant microorganism. In an embodiment, the concentration of at least one nutrient and the amount of at least one stimulus are at a ratio of from about 0.5-1.5 gr./liter to about 0.1 mM in the microbial culture. In an embodiment, such a method further includes removing the amount of ethylene produced from the microbial culture by condensing the ethylene from a gaseous to a liquid state, or wherein the amount of ethylene recovered is from about 0.5 ml to about 10 ml/liter/h.
Embodiments herein are directed to a recombinant microorganism having an improved alpha-ketoglutarate (AKG) producing ability. In certain embodiments, the recombinant microorganism expresses at least one phosphoenolpyruvate synthase (PEP) protein having an amino acid sequence at least 95% identical to SEQ ID NO. 15 by expressing a non-native PEP expressing nucleotide sequence, and wherein an amount of PEP protein produced by the recombinant microorganism is greater than that produced relative to a control microorganism lacking the non-native PEP expressing nucleotide sequence.
In certain embodiments, the recombinant microorganism expresses at least one isocitrate dehydrogenase (IDH) protein having an amino acid sequence at least 95% identical to SEQ ID NO. 20 by expressing a non-native IDH expressing nucleotide sequence, and wherein an amount of IDH protein produced by the recombinant microorganism is greater than that produced relative to a control microorganism lacking the non-native IDH expressing nucleotide sequence; wherein an amount of AKG produced by the recombinant microorganism is greater than that produced relative to the control microorganism.
In certain embodiments, the recombinant microorganism expresses at least one citrate synthase protein having an amino acid sequence at least 95% identical to SEQ ID NO. 17 by expressing a non-native citrate synthase expressing nucleotide sequence, wherein an amount of citrate synthase protein produced by the recombinant microorganism is greater than that produced relative to a control microorganism lacking the non-native citrate synthase expressing nucleotide sequence.
In certain embodiments, the recombinant microorganism contains a deletion in a glucose-1-phosphate adenylyltransferase expressing nucleotide sequence, wherein an amount of glucose-1-phosphate adenylyltransferase protein produced by the recombinant microorganism is less than that produced relative to a control microorganism lacking the deletion.
In certain embodiments, the recombinant microorganism includes a microorganism selected from the group consisting of a Cyanobacteria, a Synechococcus, Synechococcus elongatus, Synechococcus leopoliensis, Synechocystis, Anabaena, a Pseudomonas, Pseudomonas syringae, Pseudomonas savastanoi, Chlamydomonas, Chlamydomonas reinhardtii, Escherichia, Escherichia coli, Geobacteria, algae, microalgae, electrosynthesis bacteria, a photosynthetic microorganism, yeast, filamentous fungi, and a plant cell.
The foregoing summary, as well as the following detailed description of the embodiments, will be better understood when read in conjunction with the attached drawings. For the purpose of illustration, there are shown in the drawings some embodiments, which may be preferable. It should be understood that the embodiments depicted are not limited to the precise details shown. Unless otherwise noted, the drawings are not to scale.
Unless otherwise noted, all measurements are in standard metric units.
Unless otherwise noted, all instances of the words “a,” “an,” or “the” can refer to one or more than one of the word that they modify.
Unless otherwise noted, the phrase “at least one of” means one or more than one of an object. For example, “at least one nutrient” means one nutrient, more than one nutrient, or any combination thereof.
Unless otherwise noted, the term “about” refers to ±10% of the non-percentage number that is described, rounded to the nearest whole integer. For example, about 100 ml/minute, would include 90 to 110 ml/minute. Unless otherwise noted, the term “about” refers to ±5% of a percentage number. For example, about 95% would include 90 to 100%. When the term “about” is discussed in terms of a range, then the term refers to the appropriate amount less than the lower limit and more than the upper limit. For example, from about 100 to about 500 ml/minute would include from 90 to 550 ml/minute.
Unless otherwise noted, measurable properties (height, width, length, ratio etc.) as described herein are understood to be averaged measurements.
Unless otherwise noted, the terms “provide”, “provided” or “providing” refer to the supply, production, purchase, manufacture, assembly, formation, selection, configuration, conversion, introduction, addition, or incorporation of any element, amount, component, reagent, quantity, measurement, or analysis of any composition of matter, method or system of any embodiment herein.
Sequence identity is herein defined as a relationship between two or more amino acid (polypeptide or protein) sequences or two or more nucleic acid (polynucleotide) sequences, as determined by comparing the sequences. Usually, sequence identities or similarities are compared over the whole length of the sequences compared. In the art, “identity” also means the degree of sequence relatedness between amino acid or nucleic acid sequences, as the case may be, as determined by the match between strings of such sequences. “Similarity” between two amino acid sequences is determined by comparing the amino acid sequence and its conserved amino acid substitutes of one polypeptide to the sequence of a second polypeptide. “Identity” and “similarity” can be readily calculated by various methods, known to those skilled in the art. In an embodiment, sequence identity is determined by comparing the whole length of the sequences as identified herein.
Exemplary methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Exemplary computer program methods to determine identity and similarity between two sequences include e.g. the BestFit, BLASTP (Protein Basic Local Alignment Search Tool), BLASTN (Nucleotide Basic Local Alignment Search Tool), and FASTA (Altschul, S. F. et al., J. Mol. Biol. 215:403-410 (1990), publicly available from NCBI and other sources (BLAST® Manual, Altschul, S., et al., NCBI NLM NIH Bethesda, Md. 20894). A most exemplary algorithm used is EMBOSS (European Molecular Biology Open Software Suite). Exemplary parameters for amino acid sequences comparison using EMBOSS are gap open 10.0, gap extend 0.5, Blosum matrix. Exemplary parameters for nucleic acid sequences comparison using EMBOSS are gap open 10.0, gap extend 0.5, DNA full matrix (DNA identity matrix). In embodiments, it is possible to compare the DNA/protein sequences among different species to determine the homology of sequences using online data such as Gene bank, KEG, BLAST and Ensemble.
Optionally, in determining the degree of amino acid similarity, the skilled person may also take into account so-called “conservative” amino acid substitutions, as will be clear to the skilled person. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulphur-containing side chains is cysteine and methionine. Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine. Substitutional variants of the amino acid sequence disclosed herein are those in which at least one residue in the disclosed sequences has been removed and a different residue inserted in its place. Preferably, the amino acid change is conservative. Preferred conservative substitutions for each of the naturally occurring amino acids are as follows: Ala to ser; Arg to lys; Asn to gln or his; Asp to glu; Cys to ser or ala; Gln to asn; Glu to asp; Gly to pro; His to asn or gln; Ile to leu or val; Leu to ile or val; Lys to arg; gln or glu; Met to leu or ile; Phe to met, leu or tyr; Ser to thr; Thr to ser; Trp to tyr; Tyr to trp or phe; and, Val to ile or leu.
Unless otherwise noted, the term “adapted” or “codon adapted” refers to “codon optimization” of polynucleotides as disclosed herein, the sequence of which may be native or non-native, or may be adapted for expression in other microorganisms. Codon optimization adapts the codon usage for an encoded polypeptide towards the codon bias of the organism in which the polypeptide is to be expressed. Codon optimization generally helps to increase the production level of the encoded polypeptide in the host cell.
Carbon dioxide emissions resulting from the use of fossil fuels continue to rise on a global scale. Reduction of atmospheric carbon dioxide levels is a key to mitigating or reversing climate change. Carbon capture and storage (CCS) is a prominent technology for removal of industrial carbon dioxide from the atmosphere; it has been estimated that over 20 trillion tons of carbon dioxide captured from refining and other industrial processes can be transported and stored in various types of subterranean environments or storage tanks. Although CCS is a cost effective and affordable way to reduce carbon dioxide emissions compared to other currently available methods, the problem remains that the carbon dioxide is merely being stored underground until it escapes. Therefore, CCS methods do not provide a sustainable solution to reduce excess carbon dioxide in the atmosphere. Also, there is little financial incentive for industries to pump carbon dioxide into subterranean environments, unless they are forced to by environmental regulations, or they are paid to do it as part of their business model. Arguably, global warming is a crisis because it is more lucrative to produce carbon dioxide than to dispose of carbon dioxide.
There remains a need to remove excess carbon dioxide from the atmosphere in more efficient and sustainable ways. There remains a need for technologies that can harness the over-abundance of carbon dioxide to make useful products, and for other applications that are beneficial to industry and the environment.
The challenges of the limited supply of petroleum, and the harmful effects of petroleum operations on the environment, have prompted a growing emphasis on maximizing output from existing resources, and in developing renewable sources of fuels and chemicals that can minimize environmental impacts. Since ethylene is a potentially renewable feedstock, there has been a great deal of interest in developing technologies to produce ethylene from renewable sources, such as carbon dioxide and biomass. Ethylene is the most widely produced organic compound in the world, useful in a broad spectrum of industries including plastics, solvents, and textiles. Ethylene is currently produced by steam cracking fossil fuels or dehydrogenating ethane. With millions of metric tons of ethylene being produced each year, however, more than enough carbon dioxide is produced by such processes to greatly contribute to the global carbon footprint. Producing ethylene through renewable methods would accordingly help to meet the huge demand from the energy and chemical industries, while also helping to protect the environment.
Conventional methods have been developed to produce bio-ethylene using ethanol derived from corn or sugar cane. However, the production of bio-ethylene from biomass (e.g. corn and sugar cane) is a time-consuming and cost-ineffective process, requiring land, transportation, and digestion of biomass. For example, there are massive inefficiencies associated with the growing and transportation of corn and sugar cane, which by itself causes CO2 emission. A variety of microbes, including bacteria and fungi, naturally produce ethylene in small amounts. Such microbes make use of an ethylene-forming enzyme (EFE). A type of ethylene pathway, such as is found in Pseudomonas syringae and Penicillium digitatum, uses alpha-ketoglutarate (AKG) and arginine as substrates in a reaction catalyzed by an ethylene-forming enzyme. Ethylene-forming enzymes provide a promising target, because expression of a single gene can be sufficient for ethylene production. Techniques making use of heterologous expression of an EFE have been demonstrated in several microbial species, where the microbial hosts have been able to utilize a variety of carbon sources in the Calvin cycle, including lignocellulose and carbon dioxide. Plus, recent developments in cost-effective high throughput genetic sequencing technologies have led to an increased understanding of microbial gene expression. However, the currently available technologies do not produce industrially relevant quantities of ethylene through microbial activity. There remains a need for improvements in microbial bio-ethylene production that can produce ethylene at a commercial scale. There remains a need for methods to produce ethylene useful for industrial and other applications using carbon dioxide feedstocks.
Embodiments of the present disclosure can provide a benefit not only of removing carbon dioxide from the environment along with the benefit of producing a valuable organic compound capable of being sold commercially. Embodiments of the present disclosure can thus provide a renewable alternative to conventional carbon dioxide storage, by using recombinant microbial technology to convert the carbon dioxide into ethylene as a useful organic compound. One benefit of the embodiments of the present disclosure is that the methods can make it economically profitable for an oil or natural gas company to remove carbon dioxide from the environment. An oil company, or a contractor thereof, could instead of pumping carbon dioxide into a subterranean environment or leaving the sequestered carbon dioxide underground, use the carbon dioxide as a carbon source for a culture of recombinant microorganisms to convert the carbon dioxide to ethylene in a cost-effective way. Also, much the carbon dioxide generated by transportation can be avoided because the process can be practiced on-site or would be expected to consumer more carbon dioxide than it produces.
The most effective methods for protecting the environment are those methods that people actually use. The more profitable those methods are; the more likely people are to use them. One of the benefits of the methods disclosed herein is the cost-effectiveness of using a bioreactor system. Embodiments of the present disclosure can provide a benefit of engineering a photosynthetic ethylene producing microorganism, by adapting the relevant metabolic signaling pathways to produce ethylene on an industrial scale. Such embodiments can make it profitable to remove carbon dioxide from the atmosphere and to passively generate valuable organic compounds while the microbes do the work—on a scale previously unimaginable.
What would happen to the global warming crisis if it became more profitable, or just as profitable, to convert carbon dioxide into valuable organic compounds as it did to generate the carbon dioxide in the first place? The presently disclosed methods might transform energy producers from global warming companies to global cooling companies.
The present disclosure relates to recombinant microorganisms having an improved ethylene producing ability. The present disclosure relates to methods of producing ethylene, including providing a recombinant microorganism having an improved ethylene producing ability according to various embodiments herein. As a general overview of a method disclosed herein, referring to
Embodiments of Recombinant Microorganisms
The present disclosure relates to a recombinant microorganism having an improved ethylene producing ability. In such embodiments, the recombinant microorganism expresses at least one ethylene forming enzyme (EFE) protein having an amino acid sequence at least 95% identical to SEQ ID NO: 1 by expressing a non-native EFE expressing nucleotide sequence. In some embodiments, the non-native EFE expressing nucleotide sequence encodes an EFE of Pseudomonas savastanoi. In an embodiment, the EFE protein has an amino acid sequence at least 80% or at least 90% identical to SEQ ID NO: 1. In an embodiment, the EFE protein has an amino acid sequence at least 98% identical to SEQ ID NO: 1. In various embodiments, an amount of EFE protein produced by the recombinant microorganism is greater than that produced relative to a control microorganism lacking the non-native EFE expressing nucleotide sequence. In some embodiments, the amount of EFE protein produced by the recombinant microorganism is from about 5% to about 200% or more greater than that produced relative to the control microorganism lacking the non-native EFE expressing nucleotide sequence. In some embodiments, the amount of EFE protein produced by the recombinant microorganism is from about 50% to about 150% or more greater than that produced relative to the control microorganism lacking the non-native EFE expressing nucleotide sequence. In some embodiments, the amount of EFE protein produced by the recombinant microorganism is from about 75% to about 100% or more greater than that produced relative to the control microorganism lacking the non-native EFE expressing nucleotide sequence.
In an embodiment, the recombinant microorganism also expresses at least one alpha-ketoglutarate permease (AKGP) protein by expressing a non-native AKGP expressing nucleotide sequence. In an embodiment, the AKGP protein has an amino acid sequence at least 95% identical to SEQ ID NO: 2. In an embodiment, the AKGP protein has an amino acid sequence at least 80% or at least 90% identical to SEQ ID NO: 2. In an embodiment, the AKGP protein has an amino acid sequence at least 98% identical to SEQ ID NO: 2. In an embodiment, the original sequence for SEQ ID NO: 2 was from AKGP from Pseudomonas syringe, but sequence innovation was performed to improve the expression of this sequence in Synechococcus elongatus. In various embodiments, an amount of AKGP protein produced by the recombinant microorganism is greater than that produced relative to a control microorganism lacking the non-native AKGP expressing nucleotide sequence. In some embodiments, the amount of AKGP protein produced by the recombinant microorganism is from about 5% to about 200% or more greater than that produced relative to the control microorganism lacking the non-native AKGP expressing nucleotide sequence. In some embodiments, the amount of AKGP protein produced by the recombinant microorganism is from about 50% to about 150% or more greater than that produced relative to the control microorganism lacking the non-native AKGP expressing nucleotide sequence. In some embodiments, the amount of AKGP protein produced by the recombinant microorganism is from about 75% to about 100% or more greater than that produced relative to the control microorganism lacking the non-native AKGP expressing nucleotide sequence.
In various embodiments, the recombinant microorganism includes a Cyanobacteria, a Synechococcus, Synechococcus elongatus, Synechococcus leopoliensis, Synechocystis, Anabaena, a Pseudomonas, Pseudomonas syringae, Pseudomonas savastanoi, Chlamydomonas, Chlamydomonas reinhardtii, Escherichia, Escherichia coli, Geobacteria, algae, microalgae, electrosynthesis bacteria, a photosynthetic microorganism, yeast, filamentous fungi, or a plant cell. In some embodiments, the recombinant microorganism can include Saccharomyces cerevisiae, Pseudomonas putida, Trichoderma viride, Trichoderma reesei, and tobacco.
In an embodiment, the non-native EFE expressing nucleotide sequence is inserted into a bacterial vector plasmid, a nucleotide guide of a homologous recombination system, a CRISPR CAS system, a phage display system, or a combination thereof. In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 95% identical to SEQ ID NO. 3, and the non-native EFE expressing nucleotide sequence is inserted into a vector plasmid of a Chlamydomonas sp. bacterium. In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 90% identical to SEQ ID NO. 3. In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 98% identical to SEQ ID NO. 3. In an embodiment, the non-native EFE expressing nucleotide sequence is codon adapted for expression in a Chlamydomonas sp. bacterium.
In an embodiment, a non-native EFE expressing nucleotide sequence and a non-native AKGP expressing nucleotide sequence are inserted into a bacterial vector plasmid, a nucleotide guide of a homologous recombination system, a CRISPR CAS system, a phage display system, or a combination thereof. In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 95% identical to SEQ ID NO. 4, and the non-native EFE expressing nucleotide sequence and the AKGP expressing nucleotide sequence are inserted into a vector plasmid of an Escherichia sp. bacterium. In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 90% identical to SEQ ID NO. 4. In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 98% identical to SEQ ID NO. 4. In an embodiment, the non-native EFE expressing nucleotide sequence is codon adapted for expression in an Escherichia sp. bacterium, or in an Escherichia coli bacterium.
In an embodiment, the recombinant microorganism further includes a non-native AKGP expressing nucleotide sequence. In some such embodiments, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence express a combined amino acid sequence at least 95% identical to SEQ ID NO. 5. In some embodiments, the non-native expressing nucleotide sequence and non-native AKGP expression nucleotide sequence express a combined amino acid sequence at least 95% identical to SEQ ID NO. 6. In such embodiments, the combined amino acid sequence can include one or more purification tags; in an embodiment, the purification tag includes a histidine tag. In an embodiment, the purification tag includes a His-TEV sequence; in an embodiment, the His-TEV sequence includes SEQ ID NO. 10. In other embodiments, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence express a combined amino acid sequence at least 90% identical to SEQ ID NO. 5 or SEQ ID NO. 6. In other embodiments, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence express a combined amino acid sequence at least 98% identical to SEQ ID NO. 5 or SEQ ID NO. 6. In some embodiments, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence are inserted into a bacterial plasmid of a Synechococcus sp. bacterium. In an embodiment, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence include a nucleotide sequence at least 95% identical to SEQ ID NO. 7. In an embodiment, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence include a nucleotide sequence at least 90% identical to SEQ ID NO. 7. In an embodiment, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence include a nucleotide sequence at least 98% identical to SEQ ID NO. 7. In an embodiment, the non-native EFE expressing nucleotide sequence and the non-native AKGP expressing nucleotide sequence are codon adapted for expression in a Cyanobacteria. In an embodiment, the non-native EFE expressing nucleotide sequence and the non-native AKGP expressing nucleotide sequence are codon adapted for expression in a Synechococcus sp. bacterium.
Embodiments of Methods of Producing a Recombinant Microorganism
Embodiments herein are directed to methods of producing a recombinant microorganism having an improved ethylene producing ability. In an embodiment, the method includes producing a recombinant microorganism by inserting a non-native EFE expressing nucleotide sequence into a bacterial plasmid of a microorganism. In some embodiments, the non-native EFE expressing nucleotide sequence encodes an EFE of Pseudomonas savastanoi. In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 95% identical to SEQ ID NO. 3. In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 90% identical to SEQ ID NO. 3. In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 98% identical to SEQ ID NO. 3. In an embodiment, the non-native EFE expressing nucleotide sequence is codon adapted for expression in a Chlamydomonas sp. bacterium. In an embodiment, the Chlamydomonas sp. bacterium includes Chlamydomonas reinhardtii.
In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 95% identical to SEQ ID NO. 4. In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 90% identical to SEQ ID NO. 4. In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 98% identical to SEQ ID NO. 4. In an embodiment, the non-native EFE expressing nucleotide sequence is codon adapted for expression in an Escherichia sp. bacterium. In an embodiment, the Escherichia sp. bacterium includes E. coli. In an embodiment, the non-native EFE expressing nucleotide sequence includes an N-terminal NdeI cloning site (SEQ ID NO. 8 (See Appendix)). In an embodiment, the non-native EFE expressing nucleotide sequence includes one or more purification tags; in an embodiment, the purification tag includes a histidine tag. In an embodiment, the purification tag includes a histidine tag at the C-terminal end, followed by a stop codon and a HindIII cloning site (SEQ ID NO. 9 (See Appendix)).
In an embodiment, the method includes producing a recombinant microorganism by inserting a combined non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence into a bacterial plasmid of a microorganism. In one such embodiment, the combined non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence expresses an amino acid sequence at least 95% identical to SEQ ID NO. 5. In some embodiments, the non-native EFE expressing nucleotide sequence and non-native AKGP expression nucleotide sequence express a combined amino acid sequence at least 95% identical to SEQ ID NO. 6. In such embodiments, the combined amino acid sequence can include one or more purification tags; in an embodiment, the purification tag includes a histidine tag. In an embodiment, the purification tag includes a His-TEV sequence; in an embodiment, the His-TEV sequence includes SEQ ID NO. 10 (See Appendix). In other embodiments, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence express a combined amino acid sequence at least 90% identical to SEQ ID NO. 5 or SEQ ID NO. 6. In other embodiments, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence express a combined amino acid sequence at least 98% identical to SEQ ID NO. 5 or SEQ ID NO. 6. In some embodiments, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence are inserted into a bacterial plasmid of a Synechococcus sp. bacterium. In an embodiment, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence include a nucleotide sequence at least 95% identical to SEQ ID NO. 7. In an embodiment, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence include a nucleotide sequence at least 90% identical to SEQ ID NO. 7. In an embodiment, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence include a nucleotide sequence at least 98% identical to SEQ ID NO. 7. In an embodiment, the non-native EFE expressing nucleotide sequence and the non-native AKGP expressing nucleotide sequence are codon adapted for expression in a Cyanobacteria. In an embodiment, the non-native EFE expressing nucleotide sequence and the non-native AKGP expressing nucleotide sequence are codon adapted for expression in a Synechococcus sp. bacterium.
In various embodied methods, the microorganism includes a Cyanobacteria, a Synechococcus, Synechococcus elongatus, Synechococcus leopoliensis, Synechocystis, Anabaena, a Pseudomonas, Pseudomonas syringae, Pseudomonas savastanoi, Chlamydomonas, Chlamydomonas reinhardtii, Escherichia, Escherichia coli, Geobacteria, algae, microalgae, electrosynthesis bacteria, a photosynthetic microorganism, yeast, filamentous fungi, or a plant cell. In some embodiments, the recombinant microorganism can include Saccharomyces cerevisiae, Pseudomonas putida, Trichoderma viride, Trichoderma reesei, and tobacco.
In embodiments of methods herein, the non-native EFE expressing nucleotide sequence is inserted into a bacterial vector plasmid, a nucleotide guide of a homologous recombination system, a CRISPR CAS system, a phage display system, or a combination thereof. In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 95% identical to SEQ ID NO. 3, and the non-native EFE expressing nucleotide sequence is inserted into a vector plasmid of a Chlamydomonas sp. bacterium. In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 90% identical to SEQ ID NO. 3. In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 98% identical to SEQ ID NO. 3. In an embodiment, the non-native EFE expressing nucleotide sequence is codon adapted for expression in a Chlamydomonas sp. bacterium.
In an embodiment, a non-native EFE expressing nucleotide sequence and a non-native AKGP expressing nucleotide sequence are inserted into a bacterial vector plasmid, a nucleotide guide of a homologous recombination system, a CRISPR CAS system, a phage display system, or a combination thereof. In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 95% identical to SEQ ID NO. 4, and the non-native EFE expressing nucleotide sequence and the AKGP expressing nucleotide sequence are inserted into a vector plasmid of an Escherichia sp. bacterium. In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 90% identical to SEQ ID NO. 4. In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 98% identical to SEQ ID NO. 4. In an embodiment, the non-native EFE expressing nucleotide sequence is codon adapted for expression in an Escherichia sp. bacterium, or in an Escherichia coli bacterium.
In an embodiment, the recombinant microorganism further includes a non-native AKGP expressing nucleotide sequence. In some such embodiments, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence express a combined amino acid sequence at least 95% identical to SEQ ID NO. 5. In some embodiments, the non-native expressing nucleotide sequence and non-native AKGP expression nucleotide sequence express a combined amino acid sequence at least 95% identical to SEQ ID NO. 6. In such embodiments, the combined amino acid sequence can include one or more purification tags; in an embodiment, the purification tag includes a histidine tag. In an embodiment, the purification tag includes a His-TEV sequence; in an embodiment, the His-TEV sequence includes SEQ ID NO. 10. In other embodiments, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence express a combined amino acid sequence at least 90% identical to SEQ ID NO. 5 or SEQ ID NO. 6. In other embodiments, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence express a combined amino acid sequence at least 98% identical to SEQ ID NO. 5 or SEQ ID NO. 6. In some embodiments, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence are inserted into a bacterial plasmid of a Synechococcus sp. bacterium. In an embodiment, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence include a nucleotide sequence at least 95% identical to SEQ ID NO. 7. In an embodiment, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence include a nucleotide sequence at least 90% identical to SEQ ID NO. 7. In an embodiment, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence include a nucleotide sequence at least 98% identical to SEQ ID NO. 7. In an embodiment, the non-native EFE expressing nucleotide sequence and the non-native AKGP expressing nucleotide sequence are codon adapted for expression in a Cyanobacteria. In an embodiment, the non-native EFE expressing nucleotide sequence and the non-native AKGP expressing nucleotide sequence are codon adapted for expression in a Synechococcus sp. bacterium.
Embodiments of Methods of Producing Ethylene
Methods of producing ethylene are embodied herein. An embodiment of such a method includes providing a recombinant microorganism having an improved ethylene producing ability. In an embodiment, the recombinant microorganism expresses at least one ethylene forming enzyme (EFE) protein having an amino acid sequence at least 95% identical to SEQ ID NO: 1 by expressing a non-native EFE expressing nucleotide sequence, wherein an amount of EFE protein produced by the recombinant microorganism is greater than that produced relative to a control microorganism lacking the non-native EFE expressing nucleotide sequence; culturing the recombinant microorganism in a bioreactor culture vessel under conditions sufficient to produce ethylene in the bioreactor culture vessel; and harvesting ethylene from the bioreactor culture vessel.
In some embodiments of methods of producing ethylene, the non-native EFE expressing nucleotide sequence encodes an EFE of Pseudomonas savastanoi. In an embodiment, the EFE protein has an amino acid sequence at least 80% or at least 90% identical to SEQ ID NO: 1. In an embodiment, the EFE protein has an amino acid sequence at least 98% identical to SEQ ID NO: 1. In various embodiments, an amount of EFE protein produced by the recombinant microorganism is greater than that produced relative to a control microorganism lacking the non-native EFE expressing nucleotide sequence. In some embodiments, the amount of EFE protein produced by the recombinant microorganism is from about 5% to about 200% or more greater than that produced relative to the control microorganism lacking the non-native EFE expressing nucleotide sequence. In some embodiments, the amount of EFE protein produced by the recombinant microorganism is from about 50% to about 150% or more greater than that produced relative to the control microorganism lacking the non-native EFE expressing nucleotide sequence. In some embodiments, the amount of EFE protein produced by the recombinant microorganism is from about 75% to about 100% or more greater than that produced relative to the control microorganism lacking the non-native EFE expressing nucleotide sequence.
In an embodiment of methods of producing ethylene, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 95% identical to SEQ ID NO. 3. In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 80% or at least 90% identical to SEQ ID NO. 3. In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 98% identical to SEQ ID NO. 3. In an embodiment, the non-native EFE expressing nucleotide sequence is codon adapted for expression in a Chlamydomonas sp. bacterium. In an embodiment, the Chlamydomonas sp. bacterium includes Chlamydomonas reinhardtii.
In an embodiment of methods herein, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 95% identical to SEQ ID NO. 4. In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 90% identical to SEQ ID NO. 4. In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 98% identical to SEQ ID NO. 4. In an embodiment, the non-native EFE expressing nucleotide sequence is codon adapted for expression in an Escherichia sp. bacterium. In an embodiment, the Escherichia sp. bacterium includes E. coli. In an embodiment, the non-native EFE expressing nucleotide sequence includes an N-terminal NdeI cloning site (SEQ ID NO. 8). In an embodiment, the non-native EFE expressing nucleotide sequence includes one or more purification tags; in an embodiment, the purification tag includes a histidine tag. In an embodiment, the purification tag includes a histidine tag at the C-terminal end, followed by a stop codon and a HindIII cloning site (SEQ ID NO. 9).
In an embodiment, the method of producing ethylene includes producing a recombinant microorganism by inserting a combined non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence into a bacterial plasmid of a microorganism. In one such embodiment, the combined non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence expresses an amino acid sequence at least 95% identical to SEQ ID NO. 5. In some embodiments, the non-native EFE expressing nucleotide sequence and non-native AKGP expression nucleotide sequence express a combined amino acid sequence at least 95% identical to SEQ ID NO. 6. In such embodiments, the combined amino acid sequence can include one or more purification tags; in an embodiment, the purification tag includes a histidine tag. In an embodiment, the purification tag includes a His-TEV sequence; in an embodiment, the His-TEV sequence includes SEQ ID NO. 10. In other embodiments, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence express a combined amino acid sequence at least 90% identical to SEQ ID NO. 5 or SEQ ID NO. 6. In other embodiments, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence express a combined amino acid sequence at least 98% identical to SEQ ID NO. 5 or SEQ ID NO. 6. In some embodiments, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence are inserted into a bacterial plasmid of a Synechococcus sp. bacterium. In an embodiment, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence include a nucleotide sequence at least 95% identical to SEQ ID NO. 7. In an embodiment, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence include a nucleotide sequence at least 90% identical to SEQ ID NO. 7. In an embodiment, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence include a nucleotide sequence at least 98% identical to SEQ ID NO. 7. In an embodiment, the non-native EFE expressing nucleotide sequence and the non-native AKGP expressing nucleotide sequence are codon adapted for expression in a Cyanobacteria. In an embodiment, the non-native EFE expressing nucleotide sequence and the non-native AKGP expressing nucleotide sequence are codon adapted for expression in a Synechococcus sp. bacterium.
In various embodied methods, the microorganism includes a Cyanobacteria, a Synechococcus, Synechococcus elongatus, Synechococcus leopoliensis, Synechocystis, Anabaena, a Pseudomonas, Pseudomonas syringae, Pseudomonas savastanoi, Chlamydomonas, Chlamydomonas reinhardtii, Escherichia, Escherichia coli, Geobacteria, algae, microalgae, electrosynthesis bacteria, a photosynthetic microorganism, yeast, filamentous fungi, or a plant cell. In some embodiments, the recombinant microorganism can include Saccharomyces cerevisiae, Pseudomonas putida, Trichoderma viride, Trichoderma reesei, and tobacco.
In embodiments of methods herein, the non-native EFE expressing nucleotide sequence is inserted into a bacterial vector plasmid, a nucleotide guide of a homologous recombination system, a CRISPR CAS system, a phage display system, or a combination thereof. In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 95% identical to SEQ ID NO. 3, and the non-native EFE expressing nucleotide sequence is inserted into a vector plasmid of a Chlamydomonas sp. bacterium. In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 90% identical to SEQ ID NO. 3. In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 98% identical to SEQ ID NO. 3. In an embodiment, the non-native EFE expressing nucleotide sequence is codon adapted for expression in a Chlamydomonas sp. bacterium.
In an embodiment, a non-native EFE expressing nucleotide sequence and a non-native AKGP expressing nucleotide sequence are inserted into a bacterial vector plasmid, a nucleotide guide of a homologous recombination system, a CRISPR CAS system, a phage display system, or a combination thereof. In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 95% identical to SEQ ID NO. 4, and the non-native EFE expressing nucleotide sequence and the AKGP expressing nucleotide sequence are inserted into a vector plasmid of an Escherichia sp. bacterium. In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 90% identical to SEQ ID NO. 4. In an embodiment, the non-native EFE expressing nucleotide sequence has a nucleotide sequence at least 98% identical to SEQ ID NO. 4. In an embodiment, the non-native EFE expressing nucleotide sequence is codon adapted for expression in an Escherichia sp. bacterium, or in an Escherichia coli bacterium.
In an embodiment, the recombinant microorganism further includes a non-native AKGP expressing nucleotide sequence. In some such embodiments, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence express a combined amino acid sequence at least 95% identical to SEQ ID NO. 5. In some embodiments, the non-native expressing nucleotide sequence and non-native AKGP expression nucleotide sequence express a combined amino acid sequence at least 95% identical to SEQ ID NO. 6. In such embodiments, the combined amino acid sequence can include one or more purification tags; in an embodiment, the purification tag includes a histidine tag. In an embodiment, the purification tag includes a His-TEV sequence; in an embodiment, the His-TEV sequence includes SEQ ID NO. 10. In other embodiments, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence express a combined amino acid sequence at least 90% identical to SEQ ID NO. 5 or SEQ ID NO. 6. In other embodiments, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence express a combined amino acid sequence at least 98% identical to SEQ ID NO. 5 or SEQ ID NO. 6. In some embodiments, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence are inserted into a bacterial plasmid of a Synechococcus sp. bacterium. In an embodiment, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence include a nucleotide sequence at least 95% identical to SEQ ID NO. 7. In an embodiment, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence include a nucleotide sequence at least 90% identical to SEQ ID NO. 7. In an embodiment, the non-native EFE expressing nucleotide sequence and non-native AKGP expressing nucleotide sequence include a nucleotide sequence at least 98% identical to SEQ ID NO. 7. In an embodiment, the non-native EFE expressing nucleotide sequence and the non-native AKGP expressing nucleotide sequence are codon adapted for expression in a Cyanobacteria. In an embodiment, the non-native EFE expressing nucleotide sequence and the non-native AKGP expressing nucleotide sequence are codon adapted for expression in a Synechococcus sp. bacterium.
Embodiments of producing ethylene herein include culturing a recombinant microorganism in a bioreactor culture under conditions sufficient to produce ethylene in the bioreactor culture vessel. A bioreactor culture according to embodied methods can include one or more suitable reagents or growth media for supporting the growth of the recombinant microorganism culture. Such reagents or culture media can include water, one or more carbohydrates, one or more amino acids or amino acid derivatives, one or more buffers, sea water, Luria broth, Luria Bertani broth, BG-11 media, carbon dioxide, light, temperature, electricity, or combinations thereof.
An embodiment of a method of producing ethylene includes increasing an amount of ethylene production by adding at least one activator to a culture containing the recombinant microorganism located within the bioreactor culture vessel. The addition of such an activator can include increasing a concentration of one or more substrates of the EFE enzyme being expressed by the recombinant microorganism culture. Such a substrate can include alpha-ketoglutarate or arginine, or combinations thereof as well as other sources of carbon such as glycerol and glucose. In other embodiments, adding at least one activator can include adding a molecular switch. In some embodiments, adding at least one activator can include insertion of an inducible promoter upstream of the EFE gene; one such promoter includes an IPTG promoter. In such embodiments, IPTG can be added as a molecular switch to the culture media. In some embodiments, adding at least one activator can include adding one or more nutrients or stimuli to the culture. Such nutrients or stimuli can include one or more carbohydrates, one or more amino acids or amino acid derivatives, one or more EFE substrates, succinate, carbon dioxide, light, temperature, electricity, glycerol, sugars, or combinations thereof. In such embodiments, adding at least one activator to the culture can provide a benefit of controlling the cycles of ethylene production and enhancing the ethylene production rate. In some embodiments, the ethylene produced can be removed from the bioreactor culture vessel as it is produced. In such embodiments, removal of the ethylene can include condensing ethylene produced as a gas into a liquid form for removal from the bioreactor culture vessel.
In an embodiment, a method of producing ethylene includes adding CO2 to a culture atmosphere contained within the bioreactor culture vessel at rate of between about 100 ml/minute and about 500 ml/minute. In an embodiment, the method includes adding CO2 to a culture atmosphere contained within the bioreactor culture vessel at rate of between about 150 ml/minute and about 450 ml/minute. In an embodiment, the method includes adding CO2 to a culture atmosphere contained within the bioreactor culture vessel at rate of between about 250 ml/minute and about 350 ml/minute. Such embodiments can provide a benefit of enhancing or controlling the rate of ethylene production in the bioreactor culture vessel, as well as providing a benefit of converting CO2 into a useful product.
In an embodiment, a method of producing ethylene includes decreasing an amount of ethylene production by removing at least one molecular switch from the microbial culture containing the recombinant microorganism located within the bioreactor culture vessel. In an embodiment, such a method further includes controlling the amount of ethylene produced from the microbial culture by increasing or decreasing the concentration of at least one nutrient or the amount of at least one stimulus when culturing the recombinant microorganism. In an embodiment, the concentration of at least one nutrient and the amount of at least one stimulus are at a ratio of from about 0.5-1.5 gr./liter to about 0.1 mM in the microbial culture. In an embodiment, such a method further includes removing the amount of ethylene produced from the microbial culture by condensing the ethylene from a gaseous to a liquid state, or wherein the amount of ethylene recovered is from about 0.5 ml to about 10 ml/liter/h. Such embodiments can provide a benefit of controlling the amount of ethylene production by controlling the rate of activity of the Calvin cycle in the microbial culture. For example, it is possible to shift from an expression system to a growth system, where the cells are allowed to grow for 5-7 days and their growth conditions are monitored. When the cells reach an exponential growth condition (meaning that the cells are metabolically active), it is possible to shift from the growth system to an expression system, where the cells are shifted to an ethylene production cycle to produce ethylene for harvesting. This expression system might be maintained for 7 or more days.
An EFE (Ethylene Forming Enzyme) protein will be expressed and produced in Chlamydomonas reinhardtii. Plasmid pChlamy_4-EFE was generated successfully, to be used in EFE protein expression (Creative Enzymes, Shirley, N.Y.).
The polynucleotide coding for the Pseudomonas savastanoi pv. Phaseolicola EFE protein (GenBank: KPB44727.1, SEQ ID NO: 1) was cloned into the pChlamy_4 vector plasmid (ThermoFisher). Other reagents and use of instruments were provided by Creative Biostructure.
The Ethylene-forming enzyme (EFE) gene sequence from strain Pseudomonas savastanoi pv. Phaseolicola (GenBank: KPB44727.1) was used for the preparation of EFE recombinant protein. The corresponding nucleotide sequences were codon adapted for expression in Chlamydomonas reinhardtii and synthesized (SEQ ID NO: 3). The EFE construct was cloned into the pChlamy_4 vector with the Kpnl and Pstl restriction enzyme sites.
According to the pChlamy_4vector character, EFE with an N-tag was designed and generated. The pChlamy_4 vector contains the ATG initiation codon (vector ATG) for proper initiation of translation at position 497-499, found at the beginning of the Sh ble gene after the removal of Intron-1 Rbc S2. The FMDV 2A peptide gene flanking the Multiple Cloning Site 1 (MCS1) is in frame with the Sh ble gene. To use the N-terminal 6×His-V5-TEV tag, the EFE sequence was cloned in-frame after the TEV site, into the KphI/PstI digested pChlamy_4 vector. A TAA (stop codon) was designed for proper translation termination. The resulting sequence chromatogram is shown in
The polynucleotide coding for the Pseudomonas savastanoi pv. Phaseolicola EFE protein (GenBank: KPB44727.1, SEQ ID NO: 1) was cloned into the pET-30a(+) vector plasmid. The corresponding nucleotides sequences were codon adapted for expression in E. coli (SEQ ID NO: 4), containing an optional His tag at the C-terminal end followed by a stop codon and HindII site (SEQ ID NO: 9). An NdeI site was used for cloning at the 5-prime end, where the NdeI site contains an ATG start codon (SEQ ID NO: 8). E. coli BL21(DE3) competent cells were transformed with the recombinant plasmid. A single colony was inoculated into LB medium containing kanamycin; cultures were incubated in 37° C. at 200 rpm. Once cell density reached to OD=0.6-0.8 at 600 nm, 0.5 mM IPTG was introduced for induction. A pilot expression of EFE (about 44.5 kDa)_BL21(DE3) was conducted. SDS-PAGE (
SDS PAGE (left) and Western blot (right, using anti His antibody (GenScript, Cat. No. A00186)) analysis of Pilot expression of EFE in E. coli expression in construct pET 30a(+).
Lane M1: Protein marker
Lane M2: Western blot marker
Lane NC: Cell lysate without induction
Lane 1: Cell lysate with induction for 16 h at 15° C.
Lane 2: Cell lysate with induction for 4 h at 37° C.
Lane NC1: Supernatant of cell lysate without induction
Lane 3: Supernatant of cell lysate with induction for 16 h at 15 C
Lane 4: Supernatant of cell lysate with induction for 4 h at 37 C
Lane NC2: Pellet of cell lysate without induction
Lane 5: Pellet of cell lysate with induction for 16 h at 15° C.
Lane 6: Pellet of cell lysate with induction for 4 h at 37° C.
The results of SDS-PAGE and Western blots showed that EFE was expressed in E. coli. The highest EFE expression conditions were found with induction for 16 h at 15° C. that resulted in an expression level of 5 mg/L and a solubility of 30%.
A combined polynucleotide sequence (EFE_-P2A-aKGP, SEQ ID NO: 7) for expressing the EFE protein and for expressing the AKGP protein (SEQ ID NO. 2) was generated, after adaptation of the nucleotide sequence for expression in Cyanobacteria species Synechococcus elongates and Synechococcus leopoliensis (GenScript, Piscataway, N.J.). An codon adaptation analysis algorithm was used which adapts a variety of parameters that are critical to the efficiency of gene expression, including but not limited to codon usage bias, GC content, CpG dinucleotide content, mRNA secondary structure, cryptic splicing sites, premature PolyA sites, internal chi sites and ribosomal binding sites, negative CpG islands, RNA instability motif (ARE), repeat sequences (direct repeat, reverse repeat, and Dyad repeat), and restriction sites that may interfere with cloning. A codon usage bias adjustment was performed using the distribution of codon usage frequency along the length of the gene sequence, with a resulting Codon Adaptation Index (CAI) of 0.95. A CAI of 1.0 is considered to be perfect in the desired expression organism, and a CAI of greater than 0.8 is regarded as good, in terms of high gene expression level. The Frequency of Optimal Codons (FOP) was measured as the percentage distribution of favorable codons in computed codon quality groups, with the value of 100 set for the codon with the highest usage frequency for a given amino acid in the desired expression organism. A result of 80% of the codons was found in the highest codon quality group of 91-100, 3% in the second highest quality group of 81-90, and 14% in the third highest quality group of 71-80. A GC content adjustment was performed resulting in an average GC content of 56.46%, with the ideal percentage range of GC content being between 30-70%. One optional HindIII cloning site (SEQ ID NO: 12) was incorporated at the 5-prime end at position 1 of the sequence; one optional Kpnl cloning site (SEQ ID NO: 13) was incorporated at the 3-prime end at position 2524 of the sequence.
The corresponding combined EFE and AKGP amino acid sequences expressed by SEQ ID. NO. 7 have a P2A cleavage sequence (SEQ ID NO: 11) inserted between the EFE and AKGP amino acid sequences. The encoded amino acid sequence having the EFE and AKGP sequence together is shown in SEQ ID NO. 5 (EFE-P2A_pSyn_6 (No His). An optional His-TEV sequence may be included at the N-terminus (SEQ ID NO: 10), resulting in the amino acid sequence of SEQ ID NO. 6 (EFE-P2A-aKGP_pSyn_6).
1. Tailored-designed DNA constructions will be generated that encode the critical intermediates of a synthetic bio-ethylene pathway. 2. Carefully selected photosynthetic microorganisms will then be expanded for cloning and gene expression. 3. Genetic and metabolic engineering of microorganisms will then be performed for continuous production of bio-ethylene. 4. Bioengineered microorganisms will then be selected and expanded in a photobioreactor. 5. Bioreactor culture conditions (including CO2 concentration, light exposure time and wave-length, temperature, pH) will be adapted. 6. Samples will be collected and analyzed by HPLC to measure bio-ethylene synthesis. 7. Bio-ethylene production in genetically engineered microorganisms will be adapted. 8. Ethylene production processes will be scaled up.
Previous work has shown that deletion of the glgC gene leads to an increase in AKG production in Cyanobacteria. It has also been shown that over expression of the ppc gene (SEQ ID NO. 14, Genbank P74299), which encodes phosphoenolpyruvate synthase (SEQ ID NO. 15), and the gltA gene (SEQ ID NO. 16, Genbank Q59977), which encodes citrate synthase (SEQ ID NO. 17), can enhance the production of AKG as a substrate for producing other compounds. Based on this research, two categories of genes were chosen, including genes that are related directly to AKG synthesis and secretion pathways, including ppc and gltA (overexpression), and genes that are involved in energy storage pathways, including glgC (deletion), which plays a critical role in the glycogen synthesis pathway. A construct of ppc-p2A-gltA (SEQ ID NO. 18) was created for cloning into the pSyn6 plasmid before integration into Synechococcus elongatus and growth of transformed colonies. PCR was performed on pSyn6-PPC-gltA colonies to confirm the expression of the construct in Cyanobacteria; an expected band size for PPC-gltA of 4621 base pairs was observed.
For the overexpression of AKG in Cyanobacteria, a construct of an IDH gene (SEQ ID NO: 19), which encodes isocitrate dehydrogenase (SEQ ID NO. 20), was made by cloning the IDH gene into the pSyn6 plasmid. Successful cloning of the IDH gene into the pSyn6-IDH plasmid was confirmed by growth of bacterial colonies
For production of sucrose in Cyanobacteria, a construct of a cscB gene from E. coli (SEQ ID. NO. 23, Genbank P300000), which encodes sucrose permease (SEQ ID NO. 24), was made by cloning of the cscB gene into the pSyn6 plasmid. Successful cloning of the cscB gene into the pSyn6-cscB construct was confirmed by bacterial colony growth (
In addition to the overexpression of the cscB gene, and the deletion of the glgC gene, other gene targets include overexpression of the sps gene (SEQ ID NO. 25, Genbank A0A0H3KOV9), which encodes sucrose phosphate synthase (SEQ ID NO. 26); the spp gene (SEQ ID NO. 27, Genbank Q7BII3), which encodes sucrose-6-phosphatase (SEQ ID NO. 28), the glgP gene (SEQ ID NO. 29, Genbank Q31RP3), which encodes glycogen phosphorylase (SEQ ID NO. 30), and the galU gene (SEQ ID NO. 31, Genbank P0AEP3), which encodes UTP-glucose-1-phosphate uridylyltransferase (SEQ ID NO. 32), to reroute the intermediates to sucrose. In addition, deletion of the inv gene (SEQ ID NO. 33, Genbank P74573), which encodes invertase (SEQ ID NO. 34), and the ggpS gene (SEQ ID NO. 35, Genbank P74258), which encodes glucosylglycerol-phosphate synthase (SEQ ID NO. 36), will prevent conversion to alternative products; and deletion of the glgA gene (SEQ ID NO. 37, Genbank P74521), which encodes glycogen synthase (SEQ ID NO. 38), will eliminate the conversion of substrate to glycogen, which potentially can increase the sucrose yield.
For engineering production of ethylene in E. coli, gene construct pUC-EFE (SEQ ID NO. 39) was made encoding ethylene forming enzyme (EFE) under an IPTG-inducible promoter in a high copy number plasmid, pUC19. Expression of the PUC-EFE plasmid in E. coli was confirmed by colony growth on agar media supplemented with ampicillin, IPTG and X-gal, and observance of the expected band size of 2322 base pairs by gel electrophoresis and DNA analysis (
For engineering production of ethylene in E. coli, a plasmid was constructed for continuous production of EFE in E. coli. In all approaches, the EFE expression was under control of the chloroplast psbA promoter. In a first construct EFE-AKGP-psbA (SEQ ID NO. 40), the EFE and AKGP genes were placed under control of the psbA promoter (SEQ ID NO. 41) and the rrnB terminator (SEQ ID NO. 42). In a second construct EFE-psbA (SEQ ID NO. 43), only EFE gene expression was placed under control of the psbA promoter (SEQ ID NO. 41) and the T7 terminator (SEQ ID NO. 44). Both constructs were cloned into a pUC19 plasmid backbone, to take advantage of the high copy number of the plasmid, before expressing the protein in E. coli BL21 (DE3), DH5alpha, or MG1655 cell lines. A pUC-psb-EFE plasmid was constructed (SEQ ID NO. 45).
The effect of growth media, as well as AKG and arginine supplementation, on ethylene production was measured. The results indicated that a maximum ethylene production of 0.037 lb/gallon/month for E. coli BL 21 PUC19 EFE was obtained when fermented under the conditions shown in Table 1.
The results of the observed growth rate of E. coli BL 21 PUC19 EFE is shown in
This application claims the benefit of U.S. Provisional Application No. 62/942,895, filed Dec. 3, 2019 which is incorporated herein by reference.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2020/062938 | 12/2/2020 | WO |
Number | Date | Country | |
---|---|---|---|
62942895 | Dec 2019 | US |